NCT07672652Completed
Effect of Type 2 Diabetes on Biomarker Levels in Albumin Platelet-Rich Fibrin
Effect of Type 2 Diabetes on Insulin Like Growth Factor-1, Epidermal Growth Factor and Interleukin-6 Levels in Albumin Platelet-Rich Fibrin Membranes
Source: ClinicalTrials.gov · Last updated 1 Jul 2026
Brief summary (registry, in English)
Diabetes mellitus is a metabolic disease that can negatively affect wound healing and tissue repair. Albumin platelet-rich fibrin (Alb-PRF) is a blood-derived biomaterial used in periodontal and regenerative treatments. It contains growth factors and cytokines that may support tissue healing. The purpose of this study is to evaluate whether type 2 diabetes affects the biological composition of Alb-PRF. For this purpose, Alb-PRF samples obtained from individuals with type 2 diabetes will be compared with samples obtained from systemically healthy individuals. A total of 20 participants will be included in the study: 10 individuals with type 2 diabetes and 10 systemically healthy individuals. Venous blood samples will be collected from each participant, and Alb-PRF will be prepared using a standardized protocol. The prepared samples will be stored at -80°C until laboratory analysis. The levels of interleukin-6 (IL-6), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1) in Alb-PRF samples will be measured using an enzyme-linked immunosorbent assay (ELISA). These markers are related to inflammation, tissue repair, and wound healing. The results will help determine whether type 2 diabetes changes the cytokine and growth factor profile of Alb-PRF.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 17 Jun 2026
- Start date
- 15 Dec 2025
- Primary completion date
- 20 Mar 2026
- Lead sponsor
- Izmir Katip Celebi University
- Diseases
- Type 2 diabetes
- NCT number
- NCT07672652
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 15 Dec 2025 to the primary completion date, 20 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the last 6 months
Age
- Age under 18 years
Other
- Pregnancy or lactation
- Smoking
- Refusal to participate in the study or not signing the informed consent form
Who the study is looking for
- For the type 2 diabetes group:
- Diagnosis of type 2 diabetes
- HbA1c value of at least 7%
- Age over 18 years
- Non-smoker
- No use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the last 6 months
- Not pregnant or lactating
- Willingness to participate in the study and signing of the informed consent form
- For the systemically healthy group:
- No history of diabetes or prediabetes
- Age over 18 years
- Non-smoker
- No use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the last 6 months
- Not pregnant or lactating
- Willingness to participate in the study and signing of the informed consent form
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Izmir Katip Çelebi University Coordinator of this site? Confirm its status | Izmir | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.